ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE

Pre-Launch

abacavir || dolutegravir || lamivudine

ANDATABLET

Lifecycle

Pre-Launch

Data completeness

2/8 — Basic

ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE (abacavir || dolutegravir || lamivudine) by Cipla is fixed-dose combination of the hiv‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see microbiology ()]. Approved for hiv-1 infection in adults, weighing at least 6 kg.

Drug data last refreshed 1mo ago

Mechanism of Action

fixed-dose combination of the HIV‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see Microbiology ()].

Indications (2)

HIV-1 infection in adults weighing at least 6 kg

Worked on ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE at Cipla? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.